<dhhead-MANAGEMENT DISCUSSION AND ANALYSIS</dhhead-
In terms of Regulation 34 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 the Management Discussion and Analysis Report (MDAR) is structured as follows:
- INDUSTRY STRUCTURE, DEVELOPMENTS, OPPORTUNITIES & THREATS:
The global pharmaceutical market continues to expand, driven by rising healthcare needs, an ageing population, and the introduction of novel therapies. Oncology remains the fastest-growing therapeutic segment worldwide, propelled by lifestyle changes, early diagnosis, and the development of targeted and immune-based treatments. According to IQVIA projections, oncology is expected to account for a significant share of global medicine spending growth over the next decade.
In India, the pharmaceutical market is projected to reach US$35-40 billion by 2028, registering a ~10% CAGR between 2024 and 2028. Chronic therapies like Cardiac, Diabetes are expected to show higher than market growth while specialty segments like Oncology and immunology are anticipated to grow the fastest among key therapies supported by increasing patient population, improved access, and rapid adoption of innovative drugs.
The Indian market is expected to deliver high double-digit growth in Oncology over the medium term thereby providing Beta with a large runway for growth.
• Our competitive position in Indian Oncology market
Beta has a long track record of operating performance in the Indian oncology market with an established market presence in the branded oncology business in India. The Company is ranked among the leading oncology companies in India with in-house production and backward integration into key APIs. Beta is also a leading supplier of oncology products to some of the large Indian pharma companies. The Company has a track record of supplying lifesaving critical oncology drugs to leading pharma companies and hospitals in the country and has been a trusted partner for many years. Our flagship brands enjoy market leading rankings with some of the key brands holding Top 5 rank in their respective categories. We have earned strong credibility among prescribers as a trusted, high-quality supplier of oncology medicines, making these treatments more affordable for large sections of society.
Our Growth Strategy: For our Vision 2030, we have set out our key strategic priorities which, we believe, will help catapult Beta into a leading company in specialty pharmaceutical market in India and our key export markets •
• Own branded oncology: Beta is among the leading companies in Indian branded oncology market and continues to deliver higher than market growth demonstrating its ability to gain market share from competition. To sustain the momentum going forward, we have identified key strategies which will help Beta cement its place in the Indian branded segment
- Strengthening domestic leadership through robust brand-building and clinical differentiation.
- Introduce novel NDDS oncology formulations — first-of-its-kind in India — to address significant unmet clinical needs and also improve patient outcomes.
- Continuously build on our R&D competencies to launch new products encompassing:
o First to launch generics "molecules going off-patent" o Products involving complex chemistry
o Novel formulations across tablets, capsules, oral liquids, and injectables (solutions, suspensions, lyophilized) o Developing capabilities in biologics/ ADCs/ new treatment protocols through partnerships
o Developing novel routes of synthesis to bring down cost of manufacturing/ improve bioavailability/ stability of products
- Backward Integration and API manufacturing excellence: We have invested INR 35 Crores in expanding our API manufacturing capacity and a large part of it has been towards backward integration. We will continue to make our supply chain resilient while reducing our dependence on imports
- Integrated Manufacturing - Ensuring best-in-class quality through in-house capabilities and global quality accreditations.
• Exports & Global Opportunity: Beta is well positioned to leverage its low-cost, large installed manufacturing capacities to capture significant market share in semi-regulated and regulated markets. FY26 saw accelerated dossier filings in key export markets which will provide momentum for future growth. Beta is investing significant capital towards product development and filing in core export markets and has tied up with high-quality stable distributors to leverage their market reach and penetration to scale the exports business. Our filings span across multiple dosage forms including injectables and orals. We have a cumulative filings exceeding 600 over FY27 and FY28 - amplifying our growth prospects and firmly entrenching Beta as a reliable global supplier of critical lifesaving complex products. We will continue to invest and expand our formulations and API exports targeting leadership positions in our core products globally.
• IVF Product Segment: With our acquisition of 66.09% stake in Nivian in April 2026 we have forayed into IVF product segment. We aim to capture a significant share of the highly fragmented market through focused marketing to prescribers, innovative products and effective cost management. The founders of Nivian will continue to be engaged in the operations and run day-today management while leveraging Betas strengths in low-cost manufacturing and efficient supply chain operations. Nivian fits well with Betas strategy of entering and capturing large market share in fast-growing, high-quality specialty pharmaceutical businesses. Nivian provides Beta with the ideal platform to enter a new specialty pharmaceutical segment after oncology thereby extending the runway for growth for Beta.
• API expansion: We entered the API business in 2018-2019 to improve our control over the supply chain. This backward integration has yielded multiple advantages including
- Higher margins
- Control over supply chain reducing supply disruptions and import dependence
- Improved quality and supply reliability
Currently, 70% of the APIs for our formulations are manufactured in-house. API development will remain central to our new product launches and market leadership strategy while API exports will further enhance operating leverage. With the significant capex in API manufacturing in FY26 and debottlenecking of our existing capacity, we have enhanced the scope of API manufacturing which position us to serve both domestic and international customers effectively. •
• R&D Investments: Beta continues to invest significantly in new product development. We have a multi-pronged strategy to build a sustainable growth engine through new product launches. We were among the first companies in India to launch suspensions which provides ease of administration to patients and improves patient compliance. The high acceptability of the product is underscored by the fact that the new SKU launched by Beta in FY26 is among the Top 10 brands of the Company for FY26. We will continue to innovate on new technology platforms, NDDS formulations and new product launches which will reinforce Betas market position in India and export markets. Our key areas for R&D investments will continue to be:
- NDDS formulations
- "First-to-launch" off patent and new products
- New technology platforms including nano formulations
- Global licensing coupled with India focused development
• Investment in Human Resources: Beta has followed the philosophy of hiring and retaining high quality talent which helps in establishing growth and profitability of the Company in th42ng run. We have among the lowest attrition rates in the industry
in our own branded oncology business which underscores our commitment to retaining talent and providing them with a platform to excel in their field of expertise. We have demonstrated the same principle in Nivian by retaining the founders who have done remarkably well in growing Nivian to the current levels in a short span of time. The continued engagement of Nivians management is a testament to Betas philosophy of grooming exceptional talent.
• Risk Management Framework: Beta maintains a proactive risk management approach:
- Dedicated risk team continuously monitors market dynamics, commodity prices, currency fluctuations, and regulatory trends.
- Comprehensive asset insurance protects against unforeseen events.
- Preparedness for potential labour disruptions in a labour-intensive industry.
Our diversified revenue streams provide resilience, while our financial strength allows reinvestment in two key areas:
Commercial expansion - deepening domestic and international reach.
Pipeline & technology - strengthening R&D and manufacturing capabilities.
- PRODUCT WISE PERFORMANCE:
Your Company is engaged in the manufacturing of pharmaceutical products and trading of dermatology & cosmetology products.
- OVERVIEW & OUTLOOK:
The Indian pharmaceutical market will likely grow substantially, with medicine spending expected to reach US$ 40 Billion by 2028, reflecting a CAGR of 15% between 2024 and 2028. Acute therapies like anti-infectives and vitamins/minerals saw improved volumes in 2023, while chronic therapies, including cardiac and respiratory segments, continue to perform well.
Oncology and immunology are expected to lead growth across therapy areas, driven by the introduction of new treatments and the expansion of patient populations. Oncology drugs market is expected to grow at a fast clip across the world primarily driven by an ageing population and lifestyle changes making population susceptible to cancer. In India the Oncology market is expected market to grow in high double digits over the medium term reflecting strong prospects for the incumbents and companies willing to invest in R&D and innovate new products. Beta Drugs being a leader in the oncology segment has a significant runaway for growth in the Indian and global oncology market.
Our multiple segments of revenue provide us diversification benefits and substantial financial strength. Our financial strength enables us to reinvest in two key areas: building commercial capabilities both domestic and international and building a robust pipeline while expanding our technology capabilities.
- RISK AND CONCERNS:
The Company has formed a risk management team which constantly monitors the Indian and international markets and guides the management of any sort of prevailing risk to the company. The commodities prices being internationally traded are affected by the global market demand and supply forces and the dollar rate. The risk management team plays a major role here. Moreover, the industry is labour oriented and business operations of the Company may be materially affected by strikes, lock outs or work stoppage.
The Company regularly insures all its assets to enable itself in case of any mis-happening.
- INTERNAL CONTROL SYSTEM:
The Company has in place an adequate system of internal control commensurate with its size and nature of its business. These have been designed to provide reasonable assurance that all assets are safeguarded and protected against loss from unauthorized use or disposition and that all transactions are authorized, recorded and reported correctly and the business operations are conducted as per the prescribed policies and procedures of the Company. The Audit committee and the management have reviewed the adequacy of the internal control systems and suitable steps are taken to improve the same.
- FINANCIAL PERFORMANCE WITH RESPECT TO OPERATIONAL PERFORMANCE:
During the year, Revenue of the Company increased by 2.38% i.e. from Rs 22,019.96 lakhs to Rs 22,542.95 lakhs. Profit before tax is Rs 1,821.15 and Profit after tax is Rs 1,433.45 lakhs.
- HUMAN RESOURCES DEVELOPMENT AND INDUSTRIAL RELATIONS:
Your Company firmly believes that its human resources are the key enablers for the growth of the Company and important assets. Hence, the success of the Company is closely aligned to the goals of the human resources of the Company. Taking into this account, your Company continued to Invest in developing its human capital and establishing its brand on the market to attract and retain the best talent. Employee relations during the period under review continued to be healthy, cordial and harmonious at all levels and your Company is committed to maintain good relations with the employees.
- KEY FINANCIAL RATIOS:
Following are ratios for the current financial year and their comparison with preceding financial year:
| Sr. No. Ratios | As at March 31, 2026 | As at March 31, 2025 | Variance | Explanation for any change in the ratio by more than 25% as compared to the preceding year |
| 1 Debtor Turnover | 4.40 | 4.45 | -1.12% | |
| 2 Inventory turnover | 5.01 | 5.73 | -12.56% | |
| 3 Interest coverage ratio | 2.54 | 5.38 | -52.78% | EBIT increased by ^4.42 Cr, but Interest Expense surged by ^7.05 Cr |
| 4 Current Ratio | 4.02 | 4.18 | -3.82% | |
| 5 Debt-Equity Ratio | 0.90 | 1.02 | -11.76% | |
| 6 Operating Profit Margin(%) | 13% | 11.62% | 11.87% | |
| 7 Net Profit Margin (%) | 6.00% | 7.0 1% | - 14.40% | |
| 8 Return on Equity Ratio | 10.00% | 11.96% | -16.38% |
- CAUTIONARY STATEMENT:
Statement in this Management Discussion and Analysis Report, describing the Companys objectives, estimates and expectations may constitute Forward Looking Statements within the meaning of applicable laws or regulations. Actual results might differ materially from those either expressed or implied.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
